NCT01116895

A Proof of Concept Study Comparing Three Doses of an Oral Solution of LEO 22811 With a Placebo Oral Solution for the Treatment of Psoriasis Vulgaris

An International, Multi-centre, Prospective, Randomised, Double-blind, 4-arm, Placebo Controlled, Parallel Group Study With 12 Weeks Once Daily Oral Treatment in Subjects With Psoriasis Vulgaris

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 63 (actual)
• Sponsor: LEO Pharma · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

An international, multi-centre, prospective, randomised, double-blind, 4-arm, placebo controlled, parallel group study with 12 weeks once daily oral treatment in subjects with psoriasis vulgaris.

Conditions

• Psoriasis Vulgaris

Interventions

Type	Name	Description
DRUG	LEO 22811	Oral solution
DRUG	Placebo	Placebo

Timeline

• Start date: 2010-05-01
• Primary completion: 2011-03-01
• Completion: 2011-07-01
• First posted: 2010-05-05
• Last updated: 2025-03-07
• Results posted: 2018-10-03

Locations

2 sites across 2 countries: Canada, France